Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Reader Login
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 510  
Export selected to
Reference Manager
Medlars Format
RefWorks Format
BibTex Format
  Access statistics : Table of Contents
   2011| July-December  | Volume 10 | Issue 2  
    Online since November 12, 2011

  Archives   Previous Issue   Next Issue   Most popular articles   Most cited articles
Hide all abstracts  Show selected abstracts  Export selected to
  Viewed PDF Cited
Bone Scan "Hot Spot" at the Superior Lateral Orbital Margin Fronto-zygomatic Suture Uptake Characterized with Tc-99m MDP SPECT/CT
SP Thang, A. E. H Tan, A. S. W Goh
July-December 2011, 10(2):139-140
DOI:10.4103/1450-1147.89782  PMID:22144872
Findings of a solitary "hot spot" at the superior lateral orbital margin on bone scan scintigraphy is not uncommonly seen, and is often dismissed as a benign lesion. However, the exact etiology is indeterminate. We present two cases in which hybrid single photon emission computed tomography/computed tomography imaging was able to characterize and localize this uptake, demonstrating correlation to the right fronto-zygomatic suture.
  8,751 638 3
Abstracts of Invited Lectures

July-December 2011, 10(2):142-177
  6,444 412 -
Dosimetric Considerations in Radioimmunotherapy and Systemic Radionuclide Therapies: A Review
Kelvin S.H Loke, Ajit K Padhy, David C.E Ng, Anthony S.W Goh, Chaitanya Divgi
July-December 2011, 10(2):122-138
DOI:10.4103/1450-1147.89780  PMID:22144871
Radiopharmaceutical therapy, once touted as the "magic bullet" in radiation oncology, is increasingly being used in the treatment of a variety of malignancies; albeit in later disease stages. With ever-increasing public and medical awareness of radiation effects, radiation dosimetry is becoming more important. Dosimetry allows administration of the maximum tolerated radiation dose to the tumor/organ to be treated but limiting radiation to critical organs. Traditional tumor dosimetry involved acquiring pretherapy planar scans and plasma estimates with a diagnostic dose of intended radiopharmaceuticals. New advancements in single photon emission computed tomography and positron emission tomography systems allow semi-quantitative measurements of radiation dosimetry thus allowing treatments tailored to each individual patient.
  5,278 904 15
Improved Quality of Life in Patients Treated with Peptide Radionuclides
T Traub-Weidinger, M Raderer, M Uffmann, P Angelberger, A Kurtaran, M Leimer, J Preitfellner, R Dudczak, I Virgolini
July-December 2011, 10(2):115-121
DOI:10.4103/1450-1147.89779  PMID:22144870
Peptide receptor radionuclide therapy (PRRT) has recently been established as an important treatment modality for somatostatin receptor (SSTR)-positive tumors. The purpose of this study was to evaluate the clinical response, side-effects as well as the quality of life following 90 Y-DOTA-lanreotide (DOTALAN) and/or 90 Y-DOTA-Tyr 3 -DPhe 1 -octreotide (DOTATOC) therapy in patients with progressive metastatic disease during a 6-year follow-up period. Following dosimetric evaluation with 111 In-DOTALAN and 111 In-DOTATOC, 13 patients with estimated absorbed tumor doses of >5 Gy/GBq (carcinoid, n = 5; radioiodine-negative thyroid cancer, n = 4; gastrinoma, n = 1; insulinoma, n = 1; glucagonoma, n = 1; glomus jugularis tumor, n = 1) were assigned for PRRT. A dose of 925 MBq of 90 Y-DOTALAN (four patients) or 1.85-3.7 GBq of 90 Y-DOTATOC (10 patients) was administered intravenously and repeated every 4-8 weeks. Tumor dosimetry was performed prior to and under therapy, re-staging every 2-3 months. Pain intensity, Karnofsky score and general symptoms were evaluated in order to determine quality of life. Patients were followed until death. Altogether, 53 infusions of PRRT (1.85-14.1 GBq) were administered. After the first follow-up of 3 months of 90 Y-DOTALAN therapy, stable disease (SD) was observed in one patient and progressive disease (PD) in three patients. With 90 Y-DOTATOC therapy, SD was found in all 10 patients. During the re-evaluation period (4-27 months), one patient had to be shifted from 90 Y-DOTALAN to 90 Y-DOTATOC therapy due to reduced 111 In-DOTALAN uptake after 5.5 GBq. In the first 6 months after PRRT with DOTATOC, SD was found in nine of 10 patients and PD in one patient. Thereafter, SD was observed in two patients and PD in eight patients. Nine of 13 patients after PRRT with either DOTALAN or DOTATOC died. None of the patients had experienced severe acute hematological side-effects. Transient thrombocytopenia or lymphocytopenia was seen in 10 patients after 3.7 GBq, and a skin reaction in one patient. Total accumulated kidney dose ranged between 4 and 64 Gy, with reduced creatinine clearance in two patients. Pain relief was achieved in three of three patients after ~3.7 GBq ERT within 4-6 months. Appetite, weight, Karnofsky score and general well-being had improved in patients with SD during and after therapy. Based on the results of this study conducted on a small group of patients, we conclude that PRRT may offer an alternative treatment option for SSTR-positive tumors, with only mild transient side-effects and a marked improvement in the quality of life.
  3,735 731 5
Abstracts of Poster Presentations - (Bone Pain Palliation/ Radiosynovectomy)

July-December 2011, 10(2):210-215
  3,202 265 -
Abstracts of Poster Presentations - (Benign and Malignant Thyroid Disease)

July-December 2011, 10(2):190-209
  2,589 383 -
A Decade of the Asian Regional Cooperative Council for Nuclear Medicine: A Path to Reduce Heterogeneity of Nuclear Medicine Practice in Asia
Hee-Seung Bom, June-Key Chung, Myung-Chul Lee
July-December 2011, 10(2):113-114
DOI:10.4103/1450-1147.89777  PMID:22144869
  2,496 442 1
Abstracts of Poster Presentations (NET/ PRRT/ Molecular Imaging/ Radiopharmacy)

July-December 2011, 10(2):216-225
  2,625 282 -
Welcome to Saigon
Ajit Kumar Padhy
July-December 2011, 10(2):111-112
DOI:10.4103/1450-1147.89773  PMID:22144868
  2,356 429 -
Abstracts of Poster Presentations (General Nuclear Medicine and Miscellaneous)

July-December 2011, 10(2):226-245
  2,238 358 -
4 th International Conference on Radiopharmaceutical Therapy (ICRT-2011) and 10 th AGM of ARCCNM Ho Chi Minh City, Vietnam

July-December 2011, 10(2):141-141
  1,850 400 -
Abstracts of Oral Presentations

July-December 2011, 10(2):178-189
  1,677 296 -
Abstracts of Poster Presentations (Miscellaneous)

July-December 2011, 10(2):246-248
  1,370 244 -